Why the study?
Does an externally activated antitachycardia pacemaker effectively treat drug-resistant supraventricular or ventricular tachycardia?
Does an externally activated antitachycardia pacemaker effectively treat drug-resistant supraventricular or ventricular tachycardia?
Answers are grounded in this paper and cite their sources.
An externally activated antitachycardia pacemaker can effectively treat highly selected patients with drug-resistant SVT or VT and allows for serial noninvasive electrophysiologic testing.
An Omni Orthocor 234A special device pacemaker was implanted in nine patients for treatment of drug-resistant supraventricular tachycardia (three patients) or ventricular tachycardia (six patients). This device is activated using a special external unit, which delivers from six to 15 stimuli at preselected coupling intervals ranging from 195 to 500 ms. Serial noninvasive electrophysiology studies were performed either in the hospital or on an outpatient basis using the triggered mode, which can respond to programmed chest wall stimulation. Three patients with reciprocating supraventricular tachycardia were treated effectively by this device during an average follow-up of 2.2 years. Of the six patients with stable ventricular tachycardia amenable to pacemaker termination, only four remained successful during an average follow-up of 1.9 years. Such devices may find important use in serial noninvasive electrophysiologic testing during long-term clinical follow-up. The present form of this device is inadequate for widespread application, but may be useful for highly selected individuals.
No takes yet. Share an insight, caveat, or question.
Aonuma et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: